Dextera Surgical Inc (NASDAQ:DXTR) shares traded 20.49% up during most recent session to reach at the closing price of $0.22. The stock exchanged hands 16.02 Million shares versus average trading capacity of 807.08 Million shares, yielding a market cap of $2 Million. Wall Street analysts covering the stock are projecting that the stock will reach $2.1 within the next 52-weeks. The mean target projections are based on 2 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Dextera Surgical Inc (NASDAQ:DXTR) high price target of $3.5 and with a conservative view have low price target of $0.7.
On the other hand the company has Relative Strength Index (RSI 14) of 28.03 along with Average True Range (ATR 14) of 0.09, Consequently Dextera Surgical Inc (NASDAQ:DXTR)’s weekly and monthly volatility is 23.73%, 24.12% respectively. The company’s beta value is at -0.83.
In terms of Buy, Sell or Hold recommendations, Dextera Surgical Inc (NASDAQ:DXTR) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
Currently Dextera Surgical Inc (NASDAQ:DXTR)’s shares owned by insiders are 0.3%, whereas shares owned by institutional owners are 33.9%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded -14.51%.
Dextera Surgical Inc (NASDAQ:DXTR) 52-week high price stands at $3.23 and low price stands at $0.17, its price distance from 52-week high is -93.07% while its distance from 52-week low price is 31.76%. The stock hit its 52-week high on 06/03/16, and 52-week low on 05/30/17.
Dextera Surgical Inc (NASDAQ:DXTR)’s trailing twelve month revenues are $3.1 Million, whereas its price to sales ratio for the same period is 0.65. Its book value per share for the most recent quarter is $-2.36 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.28, however its price to cash per share ratio for the same period is 0.8. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.